Erythrocyte Acetylcholinesterase is a Signaling Receptor

Carlota Saldanha* and Ana Silva Herdade

Institute of Biochemistry, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Portugal

Received Date: January 12, 2018; Published Date: January 23, 2018

*Corresponding author: Carlota Saldanha, Institute of Biochemistry, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Portugal, Email: carlotasaldanha@medicina.ulisboa.pt

Abstract

The acetylcholinesterase (AChE), is an enzyme located in the erythrocyte membrane that motivate continually questions, about its physiological function. The aim of this mini review is highlight the receptor behavior of AChE in human red blood cells for chemical signals associated with nitric oxide mobilization and efflux from erythrocytes. Data from the experimental models used are presented. Consequently, key participative proteins in the steps of the signal transduction pathways, in dependence of AChE receptor, are suggested to be further considered as potential therapeutic targets.

Keywords: Erythrocyte; Acetylcholinesterase; signaling ; Acetylcholine; Receptor

Abbreviations: RBCs: Red Blood Cells; AChE: Acetylcholinesterase; ACh: Acetylcholine; AC: Adenylyl cyclase; cAMP: cyclic Adenosine Monophosphate (cAMP)

Mini Review

The need to characterize the composition, structure and function of the red blood cells (RBCs) membrane, the presence of the acetylcholinesterase (AChE) enzyme, which kinetically resembled the brain esterase, but markedly different from the cholinesterase found in serum was evidenced [1]. Human erythrocyte AChE enzyme activity is the highest one in the mammalian scale [2,3]. The presence of AChE far away of the neuronal system raises questions about its function beyond the enzyme action. Herzand Kaplan in their revision paper pointed that after in vitro hemolysis, acetylcholinesterase activity can be recovered in the erythrocyte membrane [4]. Also the tendency to couple ion transport mechanisms across erythrocyte membrane with AChE was explored with failure [4]. Later was reported AChE enzyme activity as a biomarker of human red blood cell aging and of RBC membrane integrity [5,6]. The blood of healthy humans presents a wide variety of a gradient scale with different aged classes from older to younger erythrocytes each one showing variable amount of RBCs resulting from its natural life span of 120 days. During this period, exovesicles enriched with AChE were released from erythrocyte membrane to blood circulation resting the older erythrocyte with lower enzyme activity [5,7,8]. Considering gender the human female has higher AChE enzyme activity than the men matched in age [9].

Higher human erythrocyte AChE enzyme activity were verified in patients with glaucoma, essential hypertension, and ALS [10]. These pathologies are inflammatory vascular diseases characterized by high concentration in blood of inflammatory molecules, reactive oxygen species, and reactive nitrogen species, [10]. The RBCs AChE enzyme activity data obtained in those above mentioned vascular diseases reinforce the Da`s statement of erythrocyte AChE be considered a biomarker of inflammation [11]. Das verified also, that in blood samples of inflammatory diseases, with high enzyme activity of erythrocyte AChE, lower plasma acetylcholine (ACh) levels were obtained [11].

Acetylcholine molecule acting in the parasympathetic system and in the neuron muscular junction, was considered as a neurotransmitter during several decades. Further was also recognized also as an anti-inflammatory agent through the interplay between immune and neuronal systems, the nominated "cholinergic anti-inflammatory pathway" [12-14]. This consists in the activation of adrenergic neurons in the spleen that liberate nor-epinephrine near the T cell capable to secrete acetylcholine. This non-neuronal ACh acts on α7 subunit–containing nicotinic acetylcholine receptors expressed on macrophages which after binding induce suppression on the synthesis and on the secretion of inflammatory cytokines. Macrophages act as an interface between the brain and the immune system [15]. The activation of afferent vagus nerve by endotoxin or pro-inflammatory cytokines stimulates hypothalamic-pituitary-adrenal anti-inflammatory responses conducted by the efferent vagus nerve.
Back to erythrocyte membrane enzyme, AChE has the particularity to be inhibited by high concentrations of ACh meaning by its own natural substrate, [10,16]. So, different types of enzyme complexes may be presented namely, active, inactive and less active ones according the amount of ACh existent in the experimental medium [16,17]. The unusual AChE kinetic behavior a non-neuronal environment and the discovery of nitric oxide (NO) produced in the lumen of rabbit aortic endothelium cells under the presence ACh, raised the question if there is NO inside erythrocytes [18]. NO was observed, in erythrocytes with added ACh, by fluorescence microscopy [19]. Human erythrocyte suspensions, in presence of ACh, were loaded with the permeable non fluorescent probe diaminofluoresceine-2 diacetate (DAF-2Da). Intra erythrocyte fluorescence intensity of triazolofluorescein (DAF-2T) was visualized as a result from the reaction between NO and the 4,5- dianimofluorescein. We concluded that ACh, in a dose-dependent way, is able to induce NO mobilization inside the erythrocyte [19].

Acetylcholine is known to be present in human blood circulation being produced by T lymphocytes and endothelial cells [20]. The circulating ACh induces vasodilation or vasoconstriction in dependence of integrity of the endothelium, via the NO synthesized and released to smooth muscle [21]. Also the NO released from endothelial cells can move to the lumen of the vessels where in the blood circulation is captured by free hemoglobin or scavenged by erythrocyte present [22]. The erythrocyte NO-heme-hemoglobin adduct or nitrosohemoglobin is formed at high tissues oxygen tension, for example, when deoxygenated blood enters into the vascular bed of pulmonary circulation [23]. After NO is transferred to the thiol group of cysteine β 93 of Hb forming S-nitrosohemoglobin (SNOHb) considered as a NO reservoir molecule [23]. Low tissue oxygen tension is perceived by erythrocytes with occurrence of structural allosteric transitions in SNOHb which favor the transfer of its NO to the thiol group of band 3 protein, allowing the NO efflux from erythrocytes to the capillaries spreading those tissues [24].

In in vitro studies with erythrocytes obtained from healthy donors under the presence of ACh it was evidenced increased of NO efflux, erythrocyte deformability (EE) and decreased erythrocyte aggregation and hemoglobin oxygen affinity [25]. Other in vitro study with blood samples taken from patients with vascular diseases such as hypertension, hypercholesterolemia and kidney transplant, showing lower EE than healthy persons that was ameliorate by the presence of ACh [24]. A negative association between EE values and NO efflux from erythrocytes was showed in blood samples of those patients [26].

The NO efflux measurements from erythrocytes are based on the ACh signal transduction pathway through the AChE– ACh complex ( active conformation), associated with Gaiprotein, adenyl cyclase (AC) inhibition, band 3 protein phosphorylation by protein tyrosine kinase (PTK), protein kinase C (PKC) activation, phosphodiesterase-3 (PDE3) activation, and low level of adenosine triphosphate (cAMP) molecules [17,27-31]. Lower NO efflux from erythrocytes were obtained in presence of velnacrine and timolol, which are strong and moderate AChE inhibitors respectively, [27,31,32].

Erythrocyte S-nitrosoglutathione (GSNO) is other NO reservoir molecule existing inside erythrocyte but able to be secreted by the binding of ACh or timolol to AChE forming active and less active enzyme complex respectively [33]. At variance GSNO efflux from erythrocyte is null in absence of AChE substrate or inhibitor [33]. Meanwhile, inside the erythrocytes the presence of the inactive complex AChE-VM showed higher GSNO concentration in relation to the active enzyme complex AChE-ACh [27,31]. At opposite GSNO levels inside erythrocytes were lower in presence of the less active enzyme complex AChE–timolol than in the case of the active enzyme complex AChE–ACh [33,34]. From all the data obtained in the above described studies we evidenced that erythrocyte AChE beyond its enzyme activity function as a receptor for signal molecules able to induce rescue or NO efflux from human erythrocytes and its mobilization from reservoir molecules. The NO derivative molecules inside them as nitrite, nitrate and peroxynitrite were also quantified in all mentioned studies.

The key protein molecules participants in the chemical signal transduction mechanism of NO under AChE receptor once identified were submitted to inhibitors or activators in in vitro models of hyper fibrinogenemia [35,36]. The acute phase protein fibrinogen binds to RBCs membrane CD47protein partner of the Rh macro-complex which is connected to the cytoskeleton via protein 4.2, and interacts also with the major RBC macro- complex band 3 protein [37]. The presence of AChE-ACh and AChE-timolol complexes in RBCs induced the return to normal values the higher NO efflux obtained under high fibrinogen concentration [35,38-40]. Consequently this NO scavenged avoids the increase concentrations of the reactive nitrogen and oxygen species present in inflammatory conditions. Remembering that the inflammatory response is systematically associated with variable degree of endothelium dysfunction, high plasma ACh and fibrinogen concentrations, the above data are in accordance with others that consider acetylcholine as anti-inflammatory agent. Our studies performed in vivo with animal models of inflammation demonstrated the anti-inflammatory function of ACh [41].

The erythrocytes obtained from blood samples of patients with open glaucoma evidenced ex-vivo higher NO efflux values, internal GSNO levels and AChE enzyme activity values, than those assessed in erythrocytes of healthy persons [34,42]. With these data we can understand the therapeutic efficacy of forskolin in glaucoma patients [43]. Forskolin is AC activator, meaning synthesis of cAMP levels inside RBCs, that reverted the higher NO efflux from erythrocytes model of hyper fibrinogenemia [44]. Fibrinogen binding to RBCs augmented the NO efflux under lower levels of cAMP [36]. It will be necessary to confirm in glaucoma patients under forskolin therapy whether normalization of NO

**How to cite this article:** Carlota Saldanha and Ana Silva Herdades. Erythrocyte Acetylcholinesterase is a Signaling Receptor. Nov Appro Drug Des Dev 2018; 3(4) : 555617 DOI: 10.19080/NAPDD.2018.03.555617.
eflux and lower nitrogen reactive species occur [34,44]. Also NO donors like nitroglycerin acts in treatment and prevention of endothelium dysfunction [45].

Conclusion

In conclusion the proteins therapeutic targets to control the RBCs bioavailability in NO (eflux or scavenge) in inflammatory vascular disease are AChE, AC, Gi , PTP , PTK, PKC, P13K and PD3 . Some activators and inhibitors of those proteins are already disposal for examples acetylcholine, velnacrine, timolol, adrenaline, forskolin, valsartan, wortmannin derivate and iloprost.

Acknowledgment

This work was funded by Fundação para a Ciência e Tecnologia: LISBOA-01-01-45-FEDER-007391, project cofunded by FEDER, through POR Lisboa 2020 - Programa Operacional Regional de Lisboa, Lisboa, Portugal 2020. The author is also grateful to Emilia Alves for type-writing the references.

References

1. Alles GA, Hawes RC (1940) Cholinesterases in the blood of man. J Biol Chem 133: 375-390.
2. Zajicek J, Datta N (1953) Investigation of acetylcholinesterase activity of erythrocytes, platelets and plasma in different animal species. ActaHaematol 9: 115-123.
3. Callahan JF, Kruckenberg SM (1967) Erythrocyte acetylcholinesterase activity of domestic and laboratory animals: normal levels for some species. Am J Vet Res 28: 1509-1512.
4. Fritz H, Kaplan E (1973) A Review: Human Erythrocyte Acetylcholinesterase Pediat. Res 7: 204-214.
5. Prall YG, Gambhir KK, Ampy FR (1998) Acetylcholinesterase: An enzymatic marker of human red blood cell aging. Life Sci 63: 177-184.
6. Aloni B, Livne A (1974) Acetycholinesterase as a probe for erythrocyte-membrane intactness. Biochim BiophysActa 339: 359-366.
7. Bütikofer P, Brodbeck U, Ott P (1978) Modulation of erythrocyte vesiculation by amphiphilic drugs. Biochim Biophys Acta 901: 291-295.
8. Saldanha C, Santos NC, Martins e Silva J (2004) A colorimetricprocess to visualize erythrocyte exovesicles aggregates. Biochim Mol Biol Educ 32: 250-253.
9. Hilário S, Saldanha C, Martins e Silva J (2003) An in vitro study of adrenaline effect on human erythrocyte properties in both gender. Clin Hemorheol Microcirc 28: 89-96.
10. Saldanha C (2017) Human Erythrocyte Acetylcholinesterase in Health and Disease. Molecules 22(9): pii: E1499.
11. Das UN (2007) Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 13(12): 214-221.
12. Borowikowa LV, Ivanova S, Zhang M, Yang H, Botchkina GI (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462.
13. Tracey KJ, Czura CJ, Ivanova S (2001) Mind over immunity. FASEB J. 15: 1575-1576.
14. Tracey KJ (2002) The inflammatory reflex. Nature 420 (6917): 853-859.
15. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, et al. (2005) Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 6(8): 844-851.
16. Saldanha C (1986) Acetilcolinesterase-Contribuição para o estudo cinético da enzima eritrocitária de homem. Ph.D. Thesis, Universidade Nova de Lisboa, Lisboa, Portugal.
17. Teixeira P, Duro N, Napoléão P, Saldanha C (2015) Acetylcholinesterase conformational states influence nitric oxide mobilization in theerythrocyte. J Memb. Biol 248(2): 349-354.
18. Ignarro LJ, Byrns RE, Buga GM, Wood KS (1987) Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 61(6): 866-879.
19. Mesquita R, Saldanha C, Martins-Silva J (2000) Acetylcholine induces nitric oxide production by erythrocytes in vitro. Meeting Report: First International Conference Nitric Oxide: Biology, Chemistry and Therapeutic Applications of Nitric Oxide, 3-7 June 2000. In: Nitric Oxide Biology and Chemistry 4: 313-314.
20. Fuji T, Yamada S, Yamaguchi N, Fujimoto K, Suzuki T, Kawashima K (1995) Species differences in the concentration of acetylcholine, a neurotransmitter, in whole blood and plasma. Neurosci Lett 201(3): 207-210.
21. Furchgott RF, Vanhoutte PM (1989) Endothelium-derived relaxing and contracting factors. FASEB J 3(9): 2007-2018.
22. Vaughn MW, Huang KT, Liao JC (2000) Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J Biol Chem 275(4): 2342-2348.
23. Sonveau P, Lobysheva II, Feron O, McMahon TJ (2007) Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology (Bethesda) 22: 97-112.
24. Jia L, Bonaventura C, Bonaventura J, Stamlar JS (1996) Sniitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 380(6571): 221-226.
25. Mesquita R, Pires I, Saldanha C, Martins-Silva J (2001) Effects of acetylcholine and spermimenoate on erythrocyte hemorheologic and oxygen carrying properties. Clin Hemorheol Microcirc 25(3-4): 153-163.
26. Carvalho FA, Maria AV, Bnx Nogueira JM, Guerra J, Martins-Silva J, et al. (2006) The relation between the erythrocyte nitric oxide and hemorheological parameters. Clin Hemorheol Microcirc 35(1-2): 341-347.
27. Carvalho FA, Lopes de Almeida JP, Freitas-Santos T, Saldanha C (2009) Modulation of erythrocytes acetylcholinesterase activity and its association with G protein Band 3 interactions. J Membr Biol 228(2): 89-97.
28. Almeida JP, Carvalho FA, Martins-Silva J, Saldanha C (2008) The modulation of cyclic nucleotide levels and PKC activity by acetylcholinesterase effectors in human erythrocytes. ActaBioquímica 9: 111-114.
29. Low PS, Allent DP, Zoncheck TF, Chari V, Willardson BM, et al. (1987) Tyrosine phosphorylation of band 3 inhibits peripheral protein binding. J Biol Chem 262(10): 4592-4596.
30. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, et al. (2001) Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66: 241-277.
31. Carvalho FA, Almeida JP, Fernandes IO, Freitas-Santos T, Saldanha C (2008) Non-neuronal cholinergic system and signal transduction
pathways mediated by band 3 in red blood cells. Clin Hemorheol Microcirc 40(3): 207-227.

32. Saldanha C, Teixeira P, Santos-Freitas T, Napoleão P (2013) Timolol modulates erythrocyte nitric oxide bioavailability. J Clin Exp Optalmol 4:285.

33. Teixeira P, Napoleão P, Saldanha C (2015) S-nitrosoglutathione efflux in the erythrocyte. Clin Hemorheol Microcirc 60(4): 397-404.

34. Esteves R, Freitas T, Teixeira P, Napoleão P, Neves C, et al. (2016) Erythrocytenitric oxide in glaucoma patients - ex vivo study. Clin Hemorheol Microcirc 64(4): 989-994.

35. Lopes de Almeida JP, Freitas-Santos T, Saldanha C (2011) Evidence that the degree of band 3 phosphorylation modulates human erythrocytes nitric oxide efflux in vitro model of hyperfibrinogenemia. Clin Hemorrh Microc 49(1-4): 407-416.

36. Silva-Herdade AS, Freitas T, Almeida JP, Saldanha C (2016) Fibrinogen Signaling in Erythrocyte Nitric oxide Mobilization in Presence of PI3-K and Adenyl Cyclase Inhibitors. Eur J Biom Pharm Science 3(4): 28-34.

37. De Oliveira S, Vitorino de Almeida V, Calado A, Saldanha C (2012) Integrin- associated protein (CD47) is a putative mediator for soluble fibrinogen interaction with human red blood cells membrane, Biochem Biophys Acta 1818(3): 481-490.

38. Saldanha C, Freitas T, Almeida JP (2012) Fibrinogen effects on erythrocyte nitric oxide mobilization in presence of acetylcholine. Life Sci 91(21-22): 1017-1022.

39. Saldanha C, Silva-Herdade AS (2017) Physiological properties of human erythrocytes in inflammation. J Cell Biocten 3:15-20.

40. Saldanha C, Herdade AS (2017) Erythrocyte as a therapeutic target. Nov Appro Drug Des Dev 2 (3): 1-3.

41. Saldanha C, Silva-Herdade AS. (2014) The Ubiquity Nature of Acetylcholine. Clinical & Experimental Pharmacology 4:3.

42. Zabala L, Saldanha C, Martins e Silva J, Souza-Ramalho P (1999) Red blood cell membrane integrity in primary open angle glaucoma: ex vivo and in vitro studies. Eye 13: 101-103.

43. Mutolo MG, Albanese G, Rusciano D, Pescosolido N (2016) Oral Administration of Forskolin, Homotaurine, Carnosine, and Folic Acid in Patients with Primary Open Angle Glaucoma: Changes in Intraocular Pressure, Pattern Electretinogram Amplitude, and Foveal Sensitivity. J Ocul Pharmacol Ther 32(3): 178-183.

44. Galassi F, Renieri G, Sodi A, Ucci F, Vannozzi L, et al. (2004) Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma. Br J Ophthalmol 88: 757-760.

45. Saldanha C, Lopes de Almeida JP, Silva-Herdade AS (2014) Application of nitric oxide sensor in biomedicine. Biosensors 4(1): 1-17.